Bioflorida

Website Links

Description

ALACHUA, Fla. (June 12, 2013) — RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, announced today its intent to acquire privately held Pioneer® Surgical Technology (Pioneer), headquartered in Marquette, Mich.

At BioFlorida, it’s our job to provide you -- our members, industry partners and associates -- with the available resources needed to succeed in this industry. We’re always on the road visiting and talking with members about their specific issues of concern, and seeking advice and gathering knowledge. And we want to bring that information back to you. The purpose of the Resource Center is to provide you with an excellent source of resources that you can draw on when needed. If you have information that you’d like to share with the industry please email us at admin@bioflorida.com .

Nancy Bryan joined BioFlorida in May 2013 and serves as its President and CEO. Nancy has 25 years of experience in the life sciences in commercial positions of increasing responsibility involving primary care, biologics and specialty markets. Her experience began with major pharmaceutical companies (MERCK, GlaxoSmithKline) and progressed to executive leadership positions in specialty pharmaceuticals and smaller, start-up biotech companies (Indevus Pharmaceuticals, NPS Pharmaceuticals).

Applied Genetic Technologies, a clinical-stage biotech developing treatments for orphan eye diseases, filed on Friday with the SEC to raise up to $70 million in an initial public offering. The Alachua, FL-based company, which was founded in 1999 and booked $1 million in grant and collaboration revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol AGTC. Barclays and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.

Ensure that any efforts to expand 340B drug pricing at the state level are consistent with the intended goals of the program and do not inadvertently stifle innovation within the bioscience industry. In 1992, Congress created the 340B program to help uninsured indigent patients gain better access to prescription medicines. In order to achieve that goal, Congress required pharmaceutical manufacturers to provide discounts to clinics or hospitals serving high numbers of uninsured indigent patients.

Products & services

Similar companies nearby